Presentation is loading. Please wait.

Presentation is loading. Please wait.

Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients with Heavily Pretreated Relapsed–refractory Multiple Myeloma.

Published byClyde McCormick Modified over 6 years ago

Similar presentations

Presentation on theme: "Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients with Heavily Pretreated Relapsed–refractory Multiple Myeloma."— Presentation transcript:

1 Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients with Heavily Pretreated Relapsed–refractory Multiple Myeloma in the United States  Christopher G. Pelligra, Kejal Parikh, MS, Shien Guo, PhD, Conor Chandler, Jorge Mouro, MS, Safiya Abouzaid, MPH, PharmD, Sikander Ailawadhi, MD  Clinical Therapeutics  Volume 39, Issue 10, Pages e5 (October 2017) DOI: /j.clinthera Copyright © 2017 The Authors Terms and Conditions

2 Figure 1 Diagram of health economic model illustrating health states and possible transitions. Clinical Therapeutics  , e5DOI: ( /j.clinthera ) Copyright © 2017 The Authors Terms and Conditions

3 Figure 2 Plot of progression-free survival parametric distributions for pomalidomide plus low-dose dexamethasone (POM-d), daratumumab monotherapy (DARA), and carfilzomib (CAR) used in the economic model. Clinical Therapeutics  , e5DOI: ( /j.clinthera ) Copyright © 2017 The Authors Terms and Conditions

4 Figure 3 Deterministic sensitivity analysis tornado diagrams illustrating the one-way impact of varying key parameters on pomalidomide plus low-dose dexamethasone (POM-d) versus daratumumab monotherapy (DARA) and POM-d versus carfilzomib monotherapy (CAR).AE = adverse event; BSA = body surface area; HR = hazard ratio; PF = progression-free; PFS = progression-free survival; RDI = relative dose intensity; TTF = time to treatment failure. Clinical Therapeutics  , e5DOI: ( /j.clinthera ) Copyright © 2017 The Authors Terms and Conditions

5 Figure 4 Incremental cost-effectiveness plane illustrating results of probabilistic sensitivity analyses, with effectiveness measured in incremental quality-adjusted life-years (QALYs).CAR = carfilzomib monotherapy; DARA = daratumumab monotherapy; ICER = incremental cost-effectiveness ratio. Clinical Therapeutics  , e5DOI: ( /j.clinthera ) Copyright © 2017 The Authors Terms and Conditions

6 Figure 5 Cost-effectiveness acceptability curves illustrating results of probabilistic sensitivity analyses, with effectiveness measured in quality-adjusted life-years (QALYs).CAR = carfilzomib monotherapy; DARA = daratumumab monotherapy; POM-d = pomalidomide plus low-dose dexamethasone. Clinical Therapeutics  , e5DOI: ( /j.clinthera ) Copyright © 2017 The Authors Terms and Conditions

7 Figure 6 Incremental cost-effectiveness plane illustrating results of scenario analyses, with effectiveness measured in quality-adjusted life-years (QALYs) (each point represents the results of one scenario). CAR = carfilzomib monotherapy; DARA = daratumumab monotherapy; ICER = incremental cost-effectiveness ratio. Clinical Therapeutics  , e5DOI: ( /j.clinthera ) Copyright © 2017 The Authors Terms and Conditions

8 Figure S1 Plot of observed progression-free survival data for POM-d arm of the MM-002 study and fitted parametric distributions. Clinical Therapeutics  , e5DOI: ( /j.clinthera ) Copyright © 2017 The Authors Terms and Conditions

9 Figure S2 Plot of observed post-progression survival data for POM-d arm of the MM-002 study and fitted parametric distributions. Clinical Therapeutics  , e5DOI: ( /j.clinthera ) Copyright © 2017 The Authors Terms and Conditions

10 Figure S3 Incremental cost-effectiveness plane illustrating results of probabilistic sensitivity analyses, with effectiveness measured in incremental life years.CAR=carfilzomib monotherapy; DARA=daratumumab monotherapy; ICER=incremental cost-effectiveness ratio; LY=life year. Clinical Therapeutics  , e5DOI: ( /j.clinthera ) Copyright © 2017 The Authors Terms and Conditions

11 Figure S4 Cost-effectiveness acceptability curves illustrating results of probabilistic sensitivity analyses, with effectiveness measured in life years.CAR=carfilzomib monotherapy; DARA=daratumumab monotherapy; LY=life year; POM-d=pomalidomide plus low-dose dexamethasone. Clinical Therapeutics  , e5DOI: ( /j.clinthera ) Copyright © 2017 The Authors Terms and Conditions

12 Figure S5 Incremental cost-effectiveness plane illustrating results of scenario analyses, with effectiveness measured in life years (each point represents the results of one scenario).CAR=carfilzomib monotherapy; DARA=daratumumab monotherapy; ICER=incremental cost-effectiveness ratio; LY=life year. Clinical Therapeutics  , e5DOI: ( /j.clinthera ) Copyright © 2017 The Authors Terms and Conditions

Download ppt "Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients with Heavily Pretreated Relapsed–refractory Multiple Myeloma."

Similar presentations

Long-Term Patterns of Use and Treatment Failure With Anticholinergic Agents for Overactive Bladder Michael B. Chancellor, MD, Kristen Migliaccio-Walle,

Long-Term Patterns of Use and Treatment Failure With Anticholinergic Agents for Overactive Bladder Michael B. Chancellor, MD, Kristen Migliaccio-Walle,
Effects of Rivaroxaban Versus Warfarin on Hospitalization Days and Other Health Care Resource Utilization in Patients With Nonvalvular Atrial Fibrillation:

Effects of Rivaroxaban Versus Warfarin on Hospitalization Days and Other Health Care Resource Utilization in Patients With Nonvalvular Atrial Fibrillation:
From: Cost-Effectiveness of Sacubitril-Valsartan Combination Therapy Compared With Enalapril for the Treatment of Heart Failure With Reduced Ejection Fraction.

From: Cost-Effectiveness of Sacubitril-Valsartan Combination Therapy Compared With Enalapril for the Treatment of Heart Failure With Reduced Ejection Fraction.
Bioavailability of Methadone After Sleeve Gastrectomy: A Planned Case Observation  Magnus Strømmen, RN, MSc, Arne Helland, MD, Bård Kulseng, MD, PhD, Olav.

Bioavailability of Methadone After Sleeve Gastrectomy: A Planned Case Observation  Magnus Strømmen, RN, MSc, Arne Helland, MD, Bård Kulseng, MD, PhD, Olav.
From: Cost-Effectiveness of Genotype-Guided and Dual Antiplatelet Therapies in Acute Coronary Syndrome Ann Intern Med. 2014;160(4):221-232. doi:10.7326/M13-1999.

From: Cost-Effectiveness of Genotype-Guided and Dual Antiplatelet Therapies in Acute Coronary Syndrome Ann Intern Med. 2014;160(4): doi: /M
Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.

Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.
Volume 18, Issue 2, Pages (March 2015)

Volume 18, Issue 2, Pages (March 2015)
Incidence and Risk of Cardiac Events in Patients With Previously Treated Multiple Myeloma Versus Matched Patients Without Multiple Myeloma: An Observational,

Incidence and Risk of Cardiac Events in Patients With Previously Treated Multiple Myeloma Versus Matched Patients Without Multiple Myeloma: An Observational,
Cost-Effectiveness Analysis of Stereotactic Body Radiotherapy and Radiofrequency Ablation for Medically Inoperable, Early-Stage Non–Small Cell Lung Cancer 

Cost-Effectiveness Analysis of Stereotactic Body Radiotherapy and Radiofrequency Ablation for Medically Inoperable, Early-Stage Non–Small Cell Lung Cancer 
For a copy of the poster:

For a copy of the poster:
Volume 4, Issue 10, Pages e465-e474 (October 2017)

Volume 4, Issue 10, Pages e465-e474 (October 2017)
Differences in Adverse Event Reporting Rates of Therapeutic Failure Between Two Once-daily Extended-release Methylphenidate Medications in Canada: Analysis.

Differences in Adverse Event Reporting Rates of Therapeutic Failure Between Two Once-daily Extended-release Methylphenidate Medications in Canada: Analysis.
Volume 15, Issue 2, Pages (March 2012)

Volume 15, Issue 2, Pages (March 2012)
New-onset Atrial Fibrillation Predicts Heart Failure Progression

New-onset Atrial Fibrillation Predicts Heart Failure Progression
CONFIDENTIAL Public observers

CONFIDENTIAL Public observers
San Miguel JF et al. 1 Proc EHA 2013;Abstract S1151.

San Miguel JF et al. 1 Proc EHA 2013;Abstract S1151.
Dimopoulos MA et al. Proc ASH 2012;Abstract LBA-6.

Dimopoulos MA et al. Proc ASH 2012;Abstract LBA-6.
Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,
Cost Utility of Sirolimus versus Tacrolimus for the Primary Prevention of Graft Rejection in Renal Transplant Recipients in Mexico  Kely Rely, Rosa María.

Cost Utility of Sirolimus versus Tacrolimus for the Primary Prevention of Graft Rejection in Renal Transplant Recipients in Mexico  Kely Rely, Rosa María.
A Comparison of the Efficacy of Immunomodulatory-containing Regimens in Relapsed/Refractory Multiple Myeloma: A Network Meta-analysis  Meletios Athanasios.

A Comparison of the Efficacy of Immunomodulatory-containing Regimens in Relapsed/Refractory Multiple Myeloma: A Network Meta-analysis  Meletios Athanasios.

Similar presentations

Ads by Google